Indivior Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Indivior Pharmaceuticals CEO'su Joe Ciaffoni, May2025 tarihinde atandı, in görev süresi 1.08 yıldır. in toplam yıllık tazminatı $ 18.87M olup, şirket hissesi ve opsiyonları dahil olmak üzere 3.6% maaş ve 96.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.046% ine doğrudan sahiptir ve bu hisseler $ 2.13M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.1 yıl ve 2.3 yıldır.

Anahtar bilgiler

Joe Ciaffoni

İcra Kurulu Başkanı

US$18.9m

Toplam tazminat

CEO maaş yüzdesi	3.60%
CEO görev süresi	1.1yrs
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	1.1yrs
Yönetim Kurulu ortalama görev süresi	2.3yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Jun 09

Indivior: A Stronger Business Than When I First Covered It

Summary Indivior Pharmaceuticals (INDV) is focused on opioid addiction recovery, with SUBLOCADE as its flagship product. Sustained revenue from SUBLOCADE's monthly injection model differentiates INDV from generic addiction treatments. My previous Buy rating was based on the market undervaluing SUBLOCADE's earnings power and operational turnaround potential. The investment thesis has exceeded expectations, validating the strength of INDV's business model and product economics. Read the full article on Seeking Alpha

Seeking Alpha • Apr 28

Indivior: Trying To Break Addiction

Summary Indivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key product franchise, faces competition but shows promise with expanded FDA approval and a stabilizing market share. Despite litigation risks and financial challenges, analysts remain optimistic, projecting growth in the buprenorphine market and potential stock recovery. An analysis around INDV stock follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Oct 13

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Summary Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors great risk/reward asymmetry with upside potential of 104% based on today's share price of $7.46. Temporary headwinds like Medicaid disenrollments, market share loses affecting Sublocade growth and ongoing antitrust litigations are priced in at a current forward EV/EBITDA of 2.3x. With new competition from Brixadi, Sublocade maintains 80% market share across new patients. With LAI's low-7% penetration in BMAT, having both options on the market raises awareness for both drugs. The BMAT (Buprenorphine-Medically-Assisted-Treatment) market is expected to grow at a 9.9% CAGR over the next 8 years in the US. Read the full article on Seeking Alpha

Seeking Alpha • Jul 26

Indivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback

Summary Indivior shares sold off on July 9th due to unexpected negative news from management, including the discontinuation of the schizophrenia drug Perseris and lower Sublocade guidance. Below, I argue why the market overreacted to Sublocade's lower FY24 guidance and why I expect Sublocade to continue growing. Current valuation indicates a FY24 EV/EBITDA multiple of sub 5x, offering an attractive entry point if Sublocade sales prove to be robust in the long term. Confidence in Sublocade was signalled by the board's approval of an "accelerated" $100 million repurchase program, which represents 6% of outstanding shares at the current share price of $12.5. Read the full article on Seeking Alpha

CEO Tazminat Analizi

Joe Ciaffoni'un ücretlendirmesi Indivior Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	US$252m
Dec 31 2025	US$19m	US$680k	US$210m
Sep 30 2025	n/a	n/a	US$128m
Jun 30 2025	n/a	n/a	US$108m
Mar 31 2025	n/a	n/a	-US$7m
Dec 31 2024	US$4k	n/a	US$7m

Tazminat ve Piyasa: Joe 'nin toplam tazminatı ($USD 18.87M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.92M ).

Tazminat ve Kazançlar: Joe 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Joe Ciaffoni (55 yo)

1.1yrs

Görev süresi

US$18,871,196

Tazminat

Mr. Joseph J. Ciaffoni, also known as Joe, served as Independent Non-Executive Director at Indivior Pharmaceuticals, Inc. (formerly known as Indivior PLC) since December 17, 2024 until May 2025 and serves...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joseph Ciaffoni	CEO & Director	1.1yrs	US$18.87m	0.046% $ 2.1m
Ryan Preblick	Chief Financial Officer	6yrs	US$3.59m	0.20% $ 9.4m
Christian Heidbreder	Chief Scientific Officer	11.5yrs	US$4.18m	0.17% $ 8.1m
Jeffrey Burris	Chief Legal Officer	4.5yrs	US$3.52m	0.037% $ 1.7m
Patrick Barry	Chief Commercial Officer	1yr	US$5.32m	Veri yok
Jason Thompson	Vice President of Investor Relations	no data	Veri yok	Veri yok
Kevin Espinoza	Chief Integrity & Compliance Officer	less than a year	Veri yok	Veri yok
Angela Colon-Mahoney	Chief Human Resources Officer	1.8yrs	Veri yok	Veri yok
Vanessa Procter	Executive Vice President of Corporate Affairs	less than a year	Veri yok	Veri yok
Alice Givens	Company Secretary	1.1yrs	Veri yok	Veri yok

1.1yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: INDV 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joseph Ciaffoni	CEO & Director	1.1yrs	US$18.87m	0.046% $ 2.1m
Daniel Ninivaggi	Independent Non-Executive Director	1.4yrs	US$186.70k	0.017% $ 785.4k
Juliet Thompson	Lead Independent Director	5.3yrs	US$251.56k	0.010% $ 465.3k
Stuart Kingsley	Independent Non-Executive Director	less than a year	US$140.00k	0.0046% $ 212.5k
Barbara Ryan	Independent Non-Executive Director	4yrs	US$220.47k	0.0047% $ 217.6k
Mark Stejbach	Independent Non-Executive Director	5.3yrs	US$217.51k	0.017% $ 782.6k
David Wheadon	Independent Non-Executive Chairman	2yrs	US$441.03k	0.017% $ 774.3k
Keith Humphreys	Independent Non-Executive Director	2.6yrs	US$196.79k	0.0078% $ 362.3k

2.3yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: INDV 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/17 11:55
Gün Sonu Hisse Fiyatı	2026/06/16 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Indivior Pharmaceuticals, Inc. 9 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Graham Glyn Parry	BofA Global Research
Chase Knickerbocker	Craig-Hallum Capital Group LLC
Brandon Folkes	H.C. Wainwright & Co.

Indivior Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Indivior Pharmaceuticals, Inc., Annual General Meeting, May 13, 2026

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs, Effective July 7, 2025

Indivior PLC Appoints Tony Kingsley as Independent Non-Executive Director, Effective July 1, 2025

High number of new directors

Indivior PLC, Annual General Meeting, May 08, 2025

Indivior PLC Announces Appointment of Joe Ciaffoni as Chief Executive Officer

Recent updates

Indivior Ups 2026 Outlook as SUBLOCADE Drives Revenue Growth and Share Buybacks

Indivior: A Stronger Business Than When I First Covered It

Indivior Pharmaceuticals Announces Findings From Real-World Evidence Studies on Monthly Injectable Buprenorphine (SUBLOCADE)

Indivior Q1 Results Surpass Expectations With SUBLOCADE Growth and US$175m Share Buyback

Indivior Pharmaceuticals, Inc. Raises Earnings Guidance for the Fiscal Year 2026

Indivior Pharmaceuticals, Inc. to Report Q1, 2026 Results on Apr 30, 2026

Indivior Pharmaceuticals, Inc. Announces Findings From Cost Impact Model For Monthly Injectable Buprenorphine

Indivior Pharmaceuticals, Inc., Annual General Meeting, May 13, 2026

Indivior Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full-Year 2026

Indivior Pharmaceuticals, Inc. to Report Q4, 2025 Results on Feb 26, 2026

Indivior PLC Provides Earnings Guidance for the Full Year 2026

Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine

Indivior PLC Raises Earnings Guidance for the Year 2025

Indivior PLC to Report Q3, 2025 Results on Oct 30, 2025

Indivior PLC Publishes Completes Results from a Multicenter, Open-Label Clinical Trial Published in JAMA Network Open

Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation

Indivior PLC Revises Earnings Guidance for the Year 2025

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange

Indivior PLC Announces Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Indivior PLC to Report Q2, 2025 Results on Jul 31, 2025

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs, Effective July 7, 2025

Indivior PLC Appoints Tony Kingsley as Independent Non-Executive Director, Effective July 1, 2025

Indivior PLC Presents New Data at CPDD Demonstrating That High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Indivior Intends to Cancel LSE Listing

High number of new directors

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through Ind Enabling Studies

Indivior: Trying To Break Addiction

New major risk - Negative shareholders equity

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Indivior PLC, Annual General Meeting, May 08, 2025

Indivior PLC Announces Appointment of Joe Ciaffoni as Chief Executive Officer

Indivior PLC Announces Board and Board Committee Changes

Independent Non-Executive Director recently bought US$504k worth of stock

Indivior PLC Announces Stepping Down of Mark Crossley as Chief Executive Officer

Indivior Announces FDA Approval of Label Changes for SUBLOCADE (Buprenorphine Extended-Release) Injection

Indivior plc Provides Revenue Guidance for the Year 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC Announces Delayed FDA Approval of SUBLOCADE® Label Changes

Indivior PLC to Report Q4, 2024 Results on Feb 20, 2025

Indivior PLC Appoints Daniel A. Ninivaggi to the Board as an Independent Non-Executive Director

Indivior plc Appoints David Wheadon as Chair of the Board and Chair of the Nomination Committee

High number of new directors

Independent Non-Executive Director recently bought US$251k worth of stock

Indivior PLC Announces Ryan Preblick Steps Down as Chief Financial Officer

Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment

Jerome Lande to Step Down from the Board of Indivior plc

Oaktree Capital Sends a Letter to Indivior PLC

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Price target decreased by 18% to US$19.33

Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.

Indivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback

Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024

Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression

Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Indivior PLC Announces Board Committee Changes

Indivior plc Reconfirms Earnings Guidance for 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024